ClinicalTrials.gg
Status unknownNCT02691975Updated May 13, 2020

A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

A Phase 1/2 interventional study of SHR3680 in Hormone Refractory Prostate Cancer and Metastatic Prostate Carcinoma, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 12 sites in China. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-05-13.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2020), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
197
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing rezvilutamide in Prostatic Neoplasms — 10 open to participants now, 11 under way, 3 of them phase 3. rezvilutamide · Prostatic Neoplasms.

Enrollment
5th of 18
197 · median 98
Started
2016
with 1 other
Phase 1/2
Only one
of the 18
Registered
1st of 18
by date
Lead sponsor
9 of 18
Jiangsu HengRui Medicine Co., Ltd.

Among the 18 studies testing rezvilutamide in Prostatic Neoplasms, this one is the 5th largest by enrollment, is one of 2 that started in 2016, is the only one in phase 1/2, and was the 1st registered.

Prostatic Neoplasms

7,047 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

10 of the 18 studies testing rezvilutamide in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About rezvilutamide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing rezvilutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This study evaluates the tolerability, safety, pharmacokinetics and efficacy of SHR3680 in patients with metastatic castration-resistant prostate cancer (mCPRC). All participants will receive SHR3680.

Read the detailed description

Androgenic signaling plays a pivotal role in the development of prostate cancer. Androgen deprivation therapy is the mainstay treatment for this cancer in the metastatic setting, but the disease eventually develops to castration-resistant prostate cancer (CRPC) mainly due to the overexpression of androgen receptors (AR) and continued AR activation.

SHR3680 is a novel strong AR antagonist. By competitively binding to AR, SHR3680 inhibits androgen-mediated translocation of AR to the nucleus, binding of AR to Deoxyribonucleic acid (DNA), and finally the transcription of AR target genes, thus possibly resulting in a specific and strong anti-tumor effect on prostate cancer. Unlike first-generation AR antagonists (e.g. bicalutamide), which undergoes an antagonist-to-agonist switch to stimulate AR in the setting of AR overexpression in CRPC, SHR3680 is a full antagonist of AR and thus it is supposed to be more effective for the treatment of CRPC.

03

Conditions studied

  • Hormone Refractory Prostate Cancer
  • Metastatic Prostate Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance scale 0 - 1.
  • of more than 6 months.
  • Histologically or cytologic confirmed prostate adenocarcinoma without neuroendocrine differentiation or small cell features
  • Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or orchiectomy
  • Evidence of prostate cancer progression by radiographic or PSA criteria
  • Radiological evidence of distant lesions
  • Serum testosterone level \< 1.7 nmol/L (50 ng/dL) at the screening visit
  • Adequate hepatic, renal, heart, and hematologic functions ( > 80 × 10e9/L, neutrophil > 1.5 × 10e9/L, >90 g/L,total and creatinine within (ULN), and serum transaminase≤1.5×the ULN).
  • Signed and dated .Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure.

Exclusion criteria

Exclusion Criteria:

  • Treatment with androgen receptor antagonists, 5-alpha reductase inhibitors, estrogens, or chemotherapy within 4 weeks of enrollment or plans to initiate treatment with any of these drugs during the study
  • Prior treatment with enzalutamide, abiraterone, or ketoconazole for prostate cancer
  • History of seizure or any conditions that may predispose to seizure
  • Concurrent or planned treatment with , medications known to have seizure potential, or herbal products known to decrease PSA levels
  • Planned to initiate any other anti-tumor therapies during the study
  • Less than 4 weeks from the last clinical trial
  • Evidence of or primary tumors
  • cardiovascular diseases
  • Abuse of alcohol or drugs
  • Severe concurrent disease, infection, or bone that, in the judgment of the investigator, would make the patient inappropriate for enrollment
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
197 participants (actual)

Study arms

  • Experimental
    SHR3680

    Tablet

    Drug: SHR3680

Interventions

  • SHR3680 is administrated orally, qd, 28 days as one cycle. Patients may continue SHR3680 until disease progression or unacceptable toxicity.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    For Phase 1 portion of study; maximum-tolerated dose (MTD) will be defined as the maximum dose level at which no more than one out of three subjects experience a dose-limiting toxicity (DLT) within the first 12 weeks of multiple dosing

    Time frame: 12 weeks

  2. Radiological progression-free survival

    For Phase 2 portion of study

    Time frame: 24 months

Secondary outcomes

  1. Number of participants with treatment-related adverse events

    Adverse events are assessed by CTCAE v4.0

    Time frame: 24 months

  2. The percentage of patients reaching at least a 50% reduction in prostate specific antigen (PSA) as compared to baseline at 12 weeks

    Time frame: 12 weeks

  3. Time to prostate specific antigen (PSA) progression

    Prostate specific antigen (PSA) progression is defined by the Prostate Cancer Clinical Trials Working Group (PCWG2) criteria.

    Time frame: 24 months

  4. Objective response rate

    Time frame: 24 months

  5. Quality of life

    Brief Pain Inventory (Short Form), Functional Assessment of Cancer Therapy-Prostate (v4.0)

    Time frame: 24 months

  6. Peak plasma concentration (Cmax)

    Time frame: 12 weeks

  7. Area under the plasma concentration versus time curve (AUC)

    Time frame: 12 weeks

  8. T1/2 (Half-life)

    The time required for the plasma concentration of a drug to be reduced by 50%

    Time frame: 12 weeks

07

Study locations

12 sites
  • Beijing Hosptial
    Beijing, Beijing, China
  • Chinese PLA General Hospital
    Beijing, Beijing, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing, China
  • Henan Cancer Hospital
    Zhenzhou, Henan, China
  • Hunan Cancer Hospital
    Changsha, Hunan, China
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
  • Huadong Hospital Affiliated to Fudan University
    Shanghai, Shanghai, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
08

References and documents

Publications

  • Qin X, Ji D, Gu W, Han W, Luo H, Du C, Zou Q, Sun Z, He C, Zhu S, Chong T, Yao X, Wan B, Yang X, Bai A, Jin C, Zou J, Ye D. Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial. BMC Med. 2022 Mar 4;20(1):84. doi: 10.1186/s12916-022-02263-x. PubMed 35241087 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2016 (actual). Primary completion is estimated for Dec 2020, 55 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 55 months is close to that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2016
First posted
Feb 25, 2016
StartActual
Apr 12, 2016
Primary completionEst.
Dec 1, 2020
CompletionEst.
Jun 1, 2021
Last update
May 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02691975
Responsible party
Sponsor
First posted
Feb 25, 2016
Start date
Apr 12, 2016
Primary completion
Dec 1, 2020 (estimated)
Completion
Jun 1, 2021 (estimated)
Last update
May 13, 2020

Study contacts

Dingwei Ye, M.D.
principal investigator · Fudan University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rezvilutamide

Start the discussion